Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CAMP
CAMP4 THERAPEUTICS CORPORATION
NASDAQ
$4.15
▲ UP 0.24% (0.01)

KEY STATISTICS

Market Cap$88.15 M
52w High$7.75
52w Low$1.41
Dividend Yield—
Frequency—
P/E-1.76
Volume142.06K
Shares Out.21.24M

COMPANY

LEADERSHIP

Joshua Mandel-Brehm
CHIEF EXECUTIVE
Joshua Mandel-Brehm

COMPENSATION 2026

Salary$600,000
Stock Awards$0
Incentive Plan Pay$285,750
All Other Comp.$10,500
Total$3,327,238

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 11, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
48

PRICE TARGET

Target High$15.00
Target Low$6.50
Target Median$10.75
Target Consensus$10.75

SPLIT RECORD

DATETYPERATIO
1996-03-25Forward2:1

PRICE

$4.15 ▲ UP 0.24% (+$0.01)
OVERLAYS
$4.05$4.13$4.20$4.289:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.15

About CAMP4 Therapeutics Corporation

https://www.camp4tx.com ↗

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

INDUSTRY

Biotechnology

A PRODUCT CAMP4 THERAPEUTICS CORPORATION IS KNOWN FOR

CMP-SYNGAP-01
CMP-SYNGAP-01

CMP-SYNGAP-01 is an investigational RNA therapy by CAMP4 targeting SYNGAP1-related epilepsy and intellectual disability, with toxicology studies underway to support future clinical trials.

COMPETITORS

COMPETITOR
ACAD COMPARE
PRAX COMPARE
STOK COMPARE

Revenue by Products

IconPRODUCTQ1-2023Q2-2023Q3-2023Q4-2023
Product$50.46M $46.3M ▼$37.33M ▼$31.2M ▼
Application Subscriptions And Other Services$28.05M $24.59M ▼$24.39M ▼$22.42M ▼

Revenue by Geography

MapREGIONQ1-2023Q2-2023Q3-2023Q4-2023
UNITED STATES$48.44M $39.4M ▼$32.59M ▼$29.2M ▼
EMEA— $17M $13.85M ▼$14.22M ▲
Asia Pacific$4.85M $6.16M ▲$7.64M ▲$4.82M ▼
Latin America$8.83M $7.1M ▼$5.25M ▼$3.87M ▼
All Other$1.43M $1.23M ▼$2.39M ▲$1.51M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
46
LISTED HERE
9
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.1M
IWM
0.00% · 497.2K
GSSC
0.02% · 50.7K
XRS2.DE
0.00% · 28.9K
RSSL
0.00% · 15.0K
OMFS
0.01% · 5.2K
PQ
PQSG
0.22% · 2.3K
URTY
0.00% · 1.3K
FSEG
0.03% · 465

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
98
TOP 12 OF 98 · RANKED BY POSITION SIZE
Janus Henderson Group Plc
6.3M sh · $27.88M
5am Venture Management, LLC
5.9M sh · $25.88M
Fmr LLC
4.9M sh · $21.76M
Vivo Capital, LLC
4.2M sh · $18.73M
Enavate Sciences Gp, LLC
3.8M sh · $11.36M
Blackrock Fund Advisors
2.9M sh · $42.38M
Balyasny Asset Management L.P.
2.6M sh · $11.61M
Adage Capital Partners Gp, L.L.C.
2.2M sh · $13.37M
Ah Capital Management, L.L.C.
2.1M sh · $9.37M
Vanguard Group Inc
1.7M sh · $10.26M
Stonepine Capital Management, LLC
1.4M sh · $6.13M
Harbourvest Partners LLC
1.3M sh · $5.61M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Schwab Andrew J.
Sale · 10 shares
2026-08-24
★
DIRECTOR
Schwab Andrew J.
Sale · 45.1K shares
2026-08-19
★
DIRECTOR
Schwab Andrew J.
Sale · 32.0K shares
2026-08-21
★
DIRECTOR
Schwab Andrew J.
Sale · 114.7K shares
2026-08-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 2
OUTPERFORM 1
3 GRADES IN THE LAST 12 MONTHS
Piper Sandler OVERWEIGHT JP Morgan OVERWEIGHT Leerink Partners OUTPERFORM

SECTORS PEERS

PEERPRICE
ALXO$2.00COMPARE
UNCY$5.26COMPARE
BMEA$1.73COMPARE
VXRT$0.50COMPARE
ACRV$2.06COMPARE
HYFT$1.39COMPARE
PMVP$1.22COMPARE
ATYR$0.54COMPARE